News

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 2, 2020-- ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 38^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 9:30am PT (12:30pm ET) on January 16, 2020.

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 10:00am PT (1:00pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200102005091/en/

Source: ImmunoGen Inc.

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com